GAITHERSBURG, Md. — Emergent BioSolutions Inc. announced that it would celebrate its recently completed initial public offering with the ringing of the opening bell of the New York Stock Exchange by chairman and CEO Fuad El-Hibri on Nov. 22, 2006.
“Throughout the company’s history, our people, science and technology have contributed significantly to safeguarding millions of military personnel and the general population through the delivery of a safe and effective countermeasure against the threat of anthrax infection,” El-Hibri said Nov. 21. “Tomorrow’s ringing of the opening bell is an opportunity to celebrate our company and our achievements thus far, while acknowledging the commitment and support of our employees, customers and, now, investors who continue to drive our success.”
Emergent BioSolutions’ common stock began trading on Nov. 15, 2006, under the symbol EBS. It is a biopharmaceutical company focused on the development, manufacture and commercialization of immunobiotics, such as vaccines and immune globulins, which induce or assist the body’s immune system to prevent or treat disease.
Emergent BioSolutions’marketed product, BioThrax (Anthrax Vaccine Adsorbed), is the only vaccine approved by the Food and Drug Administration for the prevention of anthrax infection.